COVID-19 pneumonia in kidney transplant recipients-Where we are?

Transpl Infect Dis. 2020 Oct;22(5):e13306. doi: 10.1111/tid.13306. Epub 2020 May 26.

Abstract

In late December 2019, China reported cases of respiratory illness in humans that involved a novel coronavirus SARS-CoV-2. On March 20, 2020, the first coronavirus disease 2019 (COVID-19) in Brazil was diagnosed, and by now, we present the report on the first case of COVID among transplant recipients in our country. A liver and kidney transplant patient with SARS-CoV-2 pneumonia without respiratory failure was treated in a clinical multimodal strategy consisting of symptomatic support therapy, immunosuppression reduction, use of anti-coronavirus drugs and heparin leading to a progressive improvement of patient symptoms till discharge. The authors also present a comprehensive review of published cases.

Keywords: COVID-19; heparin; hydroxychloroquine and azithromycin; infectious diseases; kidney and liver transplantation; nonpathogen-specifc immune parameters.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Antiviral Agents / therapeutic use
  • Brazil
  • COVID-19 / diagnosis*
  • COVID-19 / immunology
  • COVID-19 / virology
  • COVID-19 Drug Treatment
  • COVID-19 Nucleic Acid Testing
  • Graft Rejection / immunology
  • Graft Rejection / prevention & control*
  • Humans
  • Immunocompromised Host
  • Immunosuppressive Agents / adverse effects*
  • Kidney Failure, Chronic / immunology
  • Kidney Failure, Chronic / surgery
  • Kidney Transplantation / adverse effects*
  • Lung / diagnostic imaging
  • Male
  • RNA, Viral / isolation & purification
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / immunology*
  • SARS-CoV-2 / isolation & purification
  • Tomography, X-Ray Computed
  • Transplant Recipients
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Immunosuppressive Agents
  • RNA, Viral